European Bladder Cancer Therapeutics Markets

Published by: Frost & Sullivan

Published: Aug. 14, 2007 - 94 Pages

Table of Contents

1. Executive Summary

1. Overview

1. Overview of the Bladder Cancer Therapeutics Market

2. Glossary of Terms

1. List of Terms

1. Abbreviations

3. Market Overview

1. Introduction

1. Disease Characteristics

2. Epidemiology

2. Market Definitions and Segmentation

1. Definitions

2. Segmentation

4. Research Methodology at Frost & Sullivan

1. Research Objectives and Scope

1. Research Methodology

5. Industry Challenges

1. Challenges for the Bladder Cancer Market

1. Challenges Faced by Pharmaceutical Companies

6. Total European Market for Bladder Cancer Therapeutics

1. Overview and Defintions

1. Introduction

2. Market Drivers

a. Unmet Needs: Scope for New Treatment Options

b. Highest Recurrent Rate Among Cancers: Need for Lifelong Follow up and Management

c. Advancements in Bladder Cancer Diagnostic Screening Techniques: Increased Disease Detection

d. Steady Increase in Incidence of Bladder Cancer: Market Potential Increases

3. Market Restraints

a. Lack of New Products on the Horizon: Limited Growth Prospects

b. Improvements in Surgical Technique and Perioperative Care: Surgery in Certain Cases becoming the Standard of Care

4. Current Therapeutic Options - Superficial Bladder Cancer

5. Current Therapeutic Options - Invasive Bladder Cancer

6. Future Therapeutic Approaches

7. Current Treatment Guidelines

8. Market Engineering Measurement Analysis

2. Competitive Analysis

1. Profiles of Key Industry Participants

2. Market Share Analysis

3. Pipeline Analysis

7. Total Forecasts for the European Bladder Cancer Therapeutics Market

1. Forecasts

1. Patient Forecasts and Geographical Trends

2. Market Revenue Forecasts

8. Pricing and Reimbursement in Europe

1. Pricing and Reimbursement Issues

1. Pricing and Reimbursement - Country Analysis

2. Pricing and Reimbursement

9. Strategic Recommendations for the European Bladder Cancer Therapeutics Market

1. Market Engineering Recommendations

1. Strategic Recommendations

10. Database of Key Industry Participants

1. Key Industry Participants

1. Key Participants in the Bladder Cancer Therapeutics Market

11. Decision Support Databases

1. Habitual Indicators

1. Prevalence of Male Smokers

2. Prevalence of Female Smokers

3. Prevalence of Smokers

2. Healthcare Expenditure

1. Expenditure

2. Per Capita Healthcare Expenditure

3. Cancer Incidence

1. Bladder Cancer Incidence in Western Europe

2. Bladder Cancer Incidence in Selected European Countries

4. Cancer Mortality

1. Bladder Cancer Mortality in Western Europe

2. Bladder Cancer Mortality in Selected European Countries

List of Figures

Chapter 3

Bladder Cancer Therapeutics Market: Summary of Risk Factors (Europe), 2006

Bladder Cancer Therapeutics Market: TNM System for Staging (Europe), 2006

Chapter 5

Bladder Cancer Therapeutics Market: Impact of Top Industry Challenges (Europe), 2007-2013

Chapter 6

Total Bladder Cancer Therapeutics Market: Market Drivers Ranked in Order of Impact (Europe), 2007-2013

Total Bladder Cancer Therapeutics Market: Market Restraints Ranked in Order of Impact (Europe), 2007-2013

Total Bladder Cancer Therapeutics Market: Efficacy of Cytotoxic Agents in Transitional-cell Carcinoma (Europe), 2006

Total Bladder Cancer Therapeutics Market: Competitive Structure (Europe), 2006

Total Bladder Cancer Therapeutics Market: Major Branded Products (World), 2006

Total Bladder Cancer Therapeutics Market: Key Products and Their Competitors (World), 2006

Total Bladder Cancer Therapeutics Market: Pipeline Analysis—Phase III Drugs (Europe), 2006

Total Bladder Cancer Therapeutics Market: Pipeline Analysis—Phase II Drugs (Europe), 2006

Total Bladder Cancer Therapeutics Market: Pipeline Analysis—Phase I Drugs (Europe), 2006

Chapter 7

Total Bladder Cancer Therapeutics Market: Bladder Cancer Incidence by Region (Europe), 2006 Total Bladder Cancer Therapeutics Market: Bladder Cancer Mortality by Region (Europe), 2006 Total Bladder Cancer Therapeutics Market: Revenue Forecasts (Europe), 2003-2013

Chapter 9

Bladder Cancer Therapeutics Market: Strategies in the Product Life Cycle (Europe), 2006

Chapter 11

Decision Support Database: Male Smoker Prevalence in Million (World), 2002-2012

Decision Support Database: Female Smoker Prevalence in Million (World), 2002-2012

Decision Support Database: Smoker Prevalence in Million (World), 2002-2012

Decision Support Database: Total Healthcare Expenditure in Billion USD (World), 2002-2012

Decision Support Database: Per Capita Healthcare Expenditure in USD (World), 2002-2012

Decision Support Database: Bladder Cancer Incidence in '000 (Western Europe), 2002-2012

Decision Support Database: Bladder Cancer Incidence in'000 for Selected Countries (Europe), 2002-2012

Decision Support Database: Bladder Cancer Mortality (Western Europe), 2002-2012

Decision Support Database: Bladder Cancer Mortality for Selected Countries (Europe), 2002-2012

Abstract

This Frost & Sullivan research service titled European Bladder Cancer Therapeutics Markets presents a concise analysis of the market that includes challenges, factors driving growth and the revenue forecasts from 2003 to 2013. The study identifies the competitive opportunities within the market as well as strategies to exploit these opportunities and overcome industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the cytotoxic (chemotherapy therapies) and targeted therapies segments.

This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

• Cytotoxic (chemotherapy therapies)
• Targeted therapies

Technologies

The following technologies are covered in this research:

• Gene therapy
• Cytotoxic drugs
• Chemotherapy
• Radiotherapy
• Immunotherapy treatment
• Electromotive (intravesical electric current)

Market Overview

Incapacity of Existing Bladder Cancer Therapies to Improve Long-term Patient Survival Rates Create Need for Superior Treatment Methods

Despite aggressive therapy with curative intent, muscle-invasive diseases continue to be responsible for patient mortality. The failure of several developments to improve the long-term survival rate of patients with bladder cancer is creating the need for new and advanced treatment methods. "As five-year survival rates in patients receiving conventional systemic therapy for metastatic disease are poor, there is a huge unmet need for novel treatments that improve survival or increase the therapeutic ratio of systemic therapy," explains the analyst of this research service. Moreover, no new drugs for bladder cancer have entered the market in two decades, which encourages the scope for novel treatments in the market.

Emerging treatment options include new cytotoxic drugs, new targeted therapies and new biological treatments, which include gene therapy. If these treatment options can offer greater clinical efficacy compared to existing treatments, it will drive the market immensely. Novel forms of therapy are much needed for patients with metastatic disease in particular, since the current treatment is only chemotherapy and/or radiotherapy.

Market Participants Must Explore New Areas of Drug Development and Delivery to Offset Impact of Mature Product Lines

Since chemotherapy and immunotherapy treatments have been in the market for decades, they have become heavily dominated by generics and this in turn has limited growth potential. "Companies developing drugs such as cisplatin, doxorubicin and methotrexate need to explore new areas of development and different ways to grow," notes the analyst. "This can extend treatment opportunities, patient groups and could help deliver the drug more effectively."

The strategic aim in the mature stage of the product life cycle is to win over customers from competitors and increase usage by offering value-added features such as the drug delivery mechanism. Research is being carried out to improve the outcomes of Mitomycin and Bacillus Calmette-Guerin (BCG) through different delivery mechanisms such as electromotive (intravesical electric current) drug delivery.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.